Invest in SangAir

WHO estimates that there are around 49 million Sepsis cases each year, and that every Sepsis patient world-wide has an average cost of more than 320,000 SEK/patient (www.who.int). This translates to a total cost for treating 49 million patients to roughly 15,000 bn SEK/annum.

It is estimated that Sangair’s device could potentially be applicable to up to 500,000 sepsis cases worldwide each year. Considering the high costs (>320.000SEK/patient) for treatment of sepsis patients, the savings for the healthcare sector will be significant by using SangAsept.

The company aims to support healthcare and save lives, which will consequently lower public medical costs associated with treating sepsis. Healthcare costs are projected to rise due to the increasing prevalence of antibiotic-resistant bacteria, such as MRSA.

Sangair plans to sell systems to Intensive Care Units but will generate most of its revenue from recurring sales of consumable tubing sets. These tubing sets are replaced between each treatment session, allowing each system to generate substantial revenues.

Initially, Sangair plans to source the SangAsept equipment from a third-party manufacturer. The tubing kit is considered a critical component, so the company is evaluating whether to produce it in-house or continue sourcing it from a third-party manufacturer. This decision will impact future investments and may require additional funds to support revenue growth.